Jose M Baselga
Vall d'Hebron Hospital Universitari
3 papers in the Anchorcite directory, published between 2001 and 2006, cited 22,009 times in total.
ORCID profileResearch topics
- HER2/EGFR in Cancer Research · 2 papers
- Gastric Cancer Management and Outcomes · 2 papers
- Cancer Treatment and Pharmacology · 1 paper
- Head and Neck Cancer Studies · 1 paper
- Endometrial and Cervical Cancer Treatments · 1 paper
- Oral health in cancer treatment · 1 paper
Frequent co-authors
- Brian R Leyland-Jones · 2 papers
- Dennis J. Slamon · 1 paper
- Steven Shak · 1 paper
- H. Fuchs · 1 paper
- Virginia E. Paton · 1 paper
- Alex Bajamonde · 1 paper
- Wolfgang EIERMANN · 1 paper
- Janet M. Wolter · 1 paper
Papers
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine · 2001 · 11,674 citations
BACKGROUND: The HER2 gene, which encodes the growth factor receptor HER2, is amplified and HER2 is overexpressed in 25 to 30 percent of breast cancers, increasing the aggressiveness of the tumor. METHODS: We evaluated the efficacy and safety of trastuzumab,…
- Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and NeckNew England Journal of Medicine · 2006 · 5,178 citations
BACKGROUND: We conducted a multinational, randomized study to compare radiotherapy alone with radiotherapy plus cetuximab, a monoclonal antibody against the epidermal growth factor receptor, in the treatment of locoregionally advanced squamous-cell carcinoma of the head and neck. METHODS: Patients with…
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerNew England Journal of Medicine · 2005 · 5,157 citations
BACKGROUND: Trastuzumab, a recombinant monoclonal antibody against HER2, has clinical activity in advanced breast cancer that overexpresses HER2. We investigated its efficacy and safety after excision of early-stage breast cancer and completion of chemotherapy. METHODS: This international, multicenter, randomized trial…
Metadata from OpenAlex (CC0).